Group 1 - The core viewpoint of the news is that Aojing Medical has seen a stock price increase of 5.02%, reaching 21.33 yuan per share, with a total market capitalization of 2.922 billion yuan as of the report date [1] - Aojing Medical specializes in high-end biomedical materials and related medical device products, with its main business revenue composition being: 骼金 74.91%, 颅瑞 16.35%, 齿贝 4.15%, 口腔种植体 2.70%, and others 1.87% [1] - The company is located in Beijing and was established on December 22, 2004, with its listing date on May 21, 2021 [1] Group 2 - Among the top ten circulating shareholders of Aojing Medical, a fund under Rongtong Fund has entered the list, holding 2.4 million shares, which accounts for 1.75% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 1.816 billion yuan and has achieved a return of 8.57% this year, ranking 6064 out of 8155 in its category [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 135 days, with the fund's total asset scale at 5.957 billion yuan [3]

Core Insights - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of companies selected for the "Innovative Task of Biomedical Materials" initiative, with 14 companies from Beijing, including AoJing Medical Technology Co., Ltd. recognized for its "degradable semi-hydrated calcium sulfate" medical material [1][7] Company Overview - AoJing Medical is focused on the research, development, production, and sales of implantable medical devices for tissue regeneration and repair. The company pioneered the development of mineralized collagen biomimetic bone materials that closely resemble natural human bone tissue in composition and structure, achieving clinical transformation and industrialization [2][4] - The mineralized collagen biomimetic bone material consists of collagen and mineral components, such as hydroxyapatite, offering excellent biocompatibility and mechanical properties. It has been used in over one million clinical cases, demonstrating significant effectiveness in bone defect repair and regeneration [2][4] Industry Development - The Daxing Biomedical Industry Base is actively promoting the construction of specialized industrial parks, focusing on key technology research and development in high polymer materials, metal materials, and inorganic non-metallic materials [4][11] - The "Innovative Task of Biomedical Materials" initiative aims to address critical challenges in the industry, with selected companies receiving support in financing and regulatory reviews to accelerate technology transfer and application [11] - The Daxing Biomedical Industry Base has been officially named the "Zhongguancun (Daxing) Biomedical Materials Industrial Park," emphasizing its role in integrating medical and engineering sectors and fostering innovation in biomedical materials and medical devices [9][11]

Core Viewpoint - The company plans to temporarily use part of its idle raised funds, not exceeding RMB 30 million, to supplement its working capital while ensuring that the investment projects are not affected [2][4][5] Summary by Sections 1. Basic Situation of Raised Funds - The company issued 33,333,334 shares at a price of RMB 16.43 per share, raising a total of RMB 547,666,677.62 [1] - The total issuance costs amounted to RMB 49,653,236.30, including various fees [1] 2. Situation of Investment Projects - The company has a total of RMB 500,816,900.00 planned for investment in projects related to bone regeneration and artificial bone repair materials [2] - As of June 30, 2025, the unused balance of raised funds was RMB 819,299,209.1 (including interest) [2] 3. Plan for Using Idle Funds - The company intends to use up to RMB 30 million of idle raised funds for working capital, with a usage period not exceeding 12 months [2][3] - The funds will only be used for business expansion and daily operations related to the main business [3] 4. Review Procedures and Special Opinions - The board of directors and the supervisory board approved the use of idle funds, which does not require shareholder meeting approval [4] - The supervisory board believes this action will meet the company's working capital needs and improve the efficiency of idle fund usage [4] 5. Sponsor's Verification Opinion - The sponsor confirmed that the company followed necessary approval procedures and that the use of idle funds will not affect the investment projects [4][5]

Group 1 - The core viewpoint of the news is that Aojing Medical's stock performance and financing activities indicate a low level of investor confidence, with a net financing buy of -58.05 million yuan on August 26 [1] - As of August 26, Aojing Medical's total financing and securities balance is 128 million yuan, which is 4.52% of its market capitalization, indicating a low financing level compared to the past year [1] - The company has not engaged in any short selling activities on August 26, with a short selling balance of 0, suggesting a lack of bearish sentiment among investors [1] Group 2 - As of March 31, Aojing Medical had 7,905 shareholders, a decrease of 2.85% from the previous period, while the average number of circulating shares per shareholder increased by 2.93% to 17,147 shares [2] - For the first quarter of 2025, Aojing Medical reported a revenue of 42.46 million yuan, a year-on-year decrease of 10.35%, and a net profit attributable to shareholders of 1.04 million yuan, down 84.99% year-on-year [2] - The company has distributed a total of 58.67 million yuan in dividends since its A-share listing, with 22.40 million yuan distributed over the past three years [3]

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 first extraordinary general meeting of shareholders of Aojing Medical Technology Co., Ltd. comply with relevant laws and regulations [1][5][6]. Group 1: Meeting Procedures - The company published the notice for the extraordinary general meeting on June 26, 2025, which included details such as meeting time, voting methods, and agenda items, with a notice period of 15 days before the meeting [2][3]. - The meeting was held on July 11, 2025, at a specified location, and was presided over by the company's chairman, Eric Gang Hu [3]. Group 2: Attendance and Qualifications - A total of 89 shareholders and authorized agents attended the meeting, holding 26,135,097 shares, which represents a significant portion of the voting rights as of the registration date [5][6]. - The qualifications of the attendees and the convenor of the meeting were verified to be in accordance with the relevant laws and the company's articles of association [5][6]. Group 3: Voting Procedures and Results - The voting process combined both on-site and online methods, with results being counted and announced immediately after the meeting [7]. - The meeting approved the agenda items as listed in the notice, and there were no objections raised regarding the voting results [7]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including convening, attendance, and voting procedures, were conducted in compliance with applicable laws and regulations, rendering the results valid [5][7].

北京市中伦律师事务所 关于奥精医疗科技股份有限公司 法律意见书 致：奥精医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受奥精医疗科技股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2024 年年度股东大会（以下 简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》等相关法律、法规、规章、规范性文件及《奥精医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会 的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师出具本法律意见书基于公司向本所律师提供的一切原始材料、副本、复 印件等材料、口头证言均是真实、准确、完整和有效的，不存在隐瞒记载、虚假 陈述或重大遗漏，有关文件的印章和签字均真实、有效，有关副本、复印件等材 料均与原始材料一致。 法律意见书 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 ...

Company Overview - Aojing Medical Technology Co., Ltd. focuses on the research, development, production, and sales of high-end biomedical materials and related medical devices, recognized as a national high-tech enterprise [1] - The company has consistently aimed to meet clinical needs through continuous innovation in products and technology, primarily researching and developing mineralized collagen artificial bone repair materials [1] Financial Performance - As of the first quarter of 2025, Aojing Medical reported revenue of 42.46 million yuan, a year-on-year decrease of 10.35% [1] - The net profit for the same period was 1.04 million yuan, reflecting a significant year-on-year decline of 84.99% [1] - The gross profit margin stood at 60.71% [1] Market Position - Aojing Medical's latest closing price was 16.15 yuan, with a market capitalization of 2.213 billion yuan and a price-to-book ratio of 1.57 [1] - The company is among eight institutions holding shares, with a total of 35.38 million shares valued at 561 million yuan [1] Industry Comparison - Aojing Medical's price-to-earnings (P/E) ratio (TTM) is -119.23, significantly lower than the industry average of 49.02 [2] - The industry median P/E ratio is 36.25, indicating that Aojing Medical is underperforming compared to its peers [2]

4月21日，奥精医疗今日收盘16.13元，上涨10.03%，最新市净率1.54，创13天以来新低，总市值21.86亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8奥精医疗-120.67-120.671.5421.86亿行业平均 47.6950.834.76102.51亿行业中值29.8830.502.3545.38亿1天益医疗-2712.97-2712.971.7020.18亿2硕世生 物-1868.25-1868.251.1537.40亿3诺唯赞-536.80-536.802.4697.13亿4澳华内镜-516.11258.864.1354.39亿5博 晖创新-360.85-222.173.9855.39亿6康泰医学-265.2731.122.7151.59亿7华大基因-198.26216.862.05201.47亿 9睿昂基因-71.32-71.321.2411.24亿10热景生物-66.94-66.943.68119.99亿11华大智造-52.78-52.783.96316.22 亿 股东方面，截至2024年9月30日，奥精医疗股东户数9779户，较上次减少188户，户均持股市值35. ...

4月10日，奥精医疗今日收盘14.5元，上涨2.11%，最新市净率1.38，总市值19.65亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入1.48亿元，同比-19.22%；净利润488.82万元，同 比-90.95%，销售毛利率74.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)6奥精医疗-108.48-108.481.3819.65亿行业平均 46.1548.384.77102.50亿行业中值29.1329.012.3143.45亿1硕世生物-1773.70-1773.701.1136.64亿2诺唯 赞-508.88-508.882.3392.08亿3博晖创新-340.62-209.723.7552.28亿4康泰医学-270.0231.682.7652.52亿5华 大基因-198.46217.092.05201.67亿7睿昂基因-79.90-79.901.2411.56亿8热景生物-56.75-56.753.12101.72亿9 华大智造-55.34-55.344.15331.55亿10中红医疗-48.80-33.200.7743.45亿11天智航-42.43-42.434. ...

奥精医疗科技股份有限公司是一家专注于高端生物医用材料及相关医疗器械产品的研发、生产及销售的 国家级高新技术企业。自成立以来,公司始终以通过产品和技术的持续创新满足临床需求为导向,主要围 绕矿化胶原人工骨修复材料领域进行研究与开发,推出了矿化胶原人工骨修复材料医疗器械产品。先后 承担了国家"863计划"重大项目课题、"十一五"国家科技支撑计划、"十二五"国家科技支撑计划等国家 级重大研发项目。 最新一期业绩显示，2024年三季报，公司实现营业收入1.48亿元，同比-19.22%；净利润488.82万元，同 比-90.95%，销售毛利率74.46%。 4月1日，奥精医疗今日收盘16.23元，上涨2.33%，最新市净率1.55，总市值22.00亿元。 股东方面，截至2024年9月30日，奥精医疗股东户数9779户，较上次减少188户，户均持股市值35.28万 元，户均持股数量2.76万股。 来源：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)6奥精医疗-121.42-121.421.5522.00亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1 ...